Citigroup Inc. boosted its holdings in shares of Syneos Health, Inc. (NASDAQ:SYNH – Free Report) by 1,293.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 455,940 shares of the company’s stock after buying an additional 423,221 shares during the quarter. Citigroup Inc. owned approximately 0.44% of Syneos Health worth $16,241,000 at the end of the most recent reporting period.
Other institutional investors have also recently bought and sold shares of the company. OLD Mission Capital LLC acquired a new position in Syneos Health during the fourth quarter worth approximately $31,000. Mesirow Institutional Investment Management Inc. acquired a new position in Syneos Health during the first quarter worth approximately $38,000. China Universal Asset Management Co. Ltd. increased its position in Syneos Health by 33.9% during the first quarter. China Universal Asset Management Co. Ltd. now owns 1,399 shares of the company’s stock worth $50,000 after buying an additional 354 shares during the last quarter. CWM LLC increased its position in Syneos Health by 122.9% during the fourth quarter. CWM LLC now owns 1,413 shares of the company’s stock worth $52,000 after buying an additional 779 shares during the last quarter. Finally, Lazard Asset Management LLC acquired a new position in Syneos Health during the first quarter worth approximately $53,000. Institutional investors and hedge funds own 91.16% of the company’s stock.
Syneos Health Stock Up 0.1 %
NASDAQ SYNH opened at $42.54 on Tuesday. The business has a fifty day moving average price of $42.33 and a two-hundred day moving average price of $40.03. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.20 and a quick ratio of 1.20. Syneos Health, Inc. has a fifty-two week low of $22.89 and a fifty-two week high of $64.25. The stock has a market capitalization of $4.41 billion, a PE ratio of 61.65 and a beta of 1.58.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently issued reports on the company. StockNews.com assumed coverage on Syneos Health in a report on Tuesday, August 22nd. They set a “hold” rating for the company. Barclays upgraded Syneos Health from an “underweight” rating to an “equal weight” rating in a report on Wednesday, May 10th. Robert W. Baird cut Syneos Health from an “outperform” rating to a “neutral” rating in a report on Thursday, May 11th. Mizuho boosted their price objective on Syneos Health from $38.00 to $43.00 in a report on Tuesday, May 16th. Finally, Deutsche Bank Aktiengesellschaft cut Syneos Health from a “buy” rating to a “hold” rating in a research note on Thursday, May 11th. Nine investment analysts have rated the stock with a hold rating, According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $44.00.
View Our Latest Report on Syneos Health
Syneos Health Profile
Syneos Health, Inc, operates as an integrated biopharmaceutical solutions company. The company operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in Phase I to IV of clinical development.
See Also
Want to see what other hedge funds are holding SYNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syneos Health, Inc. (NASDAQ:SYNH – Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Syneos Health, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Syneos Health wasn’t on the list.
While Syneos Health currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Source: marketbeat.com
